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Hepatocellular carcinoma (HCC) in the caudate lobe remains one of the most intricate locations where various treatments tend to 
pose problems with regard to the optimal approach. Surgical resection has been regarded as the most effective treatment; 
however, isolated resection of the caudate lobe is strenuous and associated with a high rate of early recurrence. Percutaneous 
ablation might be technically difficult or impossible to perform due to the deep location of tumors and adjacent large vessels. 
Treatment with drug-eluting beads (DEB) can potentially enhance the therapeutic efficacy for patients with unresectable HCC by 
drawing on the slower, more consistent drug delivery process. We described a case of a 62-year-old man with HCC in the 
caudate lobe who was successfully treated by DEB. (Korean J Hepatol 2010;16:405-409)
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INTRODUCTION
Hepatocellular carcinoma (HCC) is a common tumor with a 
poor prognosis especially in the hepatitis B endemic country 
such as Korea. Surgical resection, liver transplantation, and 
percutaneous ablation are generally accepted as the only curative 
treatments for HCC.
1 Transcatheter arterial chemoembolization 
(TACE) is the standard first-line treatment for patients with 
inoperable and intermediate HCC, but response rates and 
evidence of a survival benefit is relatively low.
2 Although there 
are several therapeutic options for the treatment of HCC, HCC in 
the caudate lobe is regarded as a clinical hot potato owing to 
limitation of applicable therapeutic method pertinent to the 
lesion. 
Recently, drug delivery embolization system, that is drug- 
eluting beads (DEB), with the ability to sequester chemotherapeutic 
agent from solution and release it in a sustained and controlled 
mode were introduced for TACE.
3 We described a case of 
early-staged caudate HCC which was treated completely by 
TACE using DEB. 
CASE REPORT
A 62-year-old man with alcoholic cirrhosis visited outpatient 
clinic for unexplained weight loss. He had a good performance 
status (grade 0). Laboratory tests showed serum albumin level of 
5.3 g/dL, bilirubin level of 1.3 mg/dL, and prothrombin time 
international normalized ratio of 1.1. Neither ascites nor hepatic 
encephalopathy was found, which corresponded with Child-Pugh 
class A. Serologic markers for hepatitis B and C were negative. 
Serum α-fetoprotein level was 311.7 ng/mL, and PIVKA-II level 
was over 2,000 mAU/mL. Other laboratory findings including 
tumor markers and thyroid function tests were within normal 
limits. About a 5 cm sized ovoid enhancing mass in arterial phase 
involving the caudate lobe with underlying cirrhotic configuration 
of the liver was shown on the dynamic computed tomography 406  The Korean Journal of Hepatology Vol. 16. No. 4, December 2010
Figure 1. An irregularly enhanced mass measuring 5 cm in the caudate lobe with delayed wash-out was observed on dynamic CT 
(A: arterial phase, B: portal phase, coronal section). Similar signal intensity was noted on MRI (C: T1-weighted image, D: T2-weighted 
image).
   
Figure 2. (A) Celiac arteriography showed a faint hypervascular tumor staining in the caudate lobe supplied by a branch from the 
left hepatic artery. (B) Selective left hepatic arteriography clearly demonstrated the tumor (arrow heads) and a single supplying artery 
branch (arrow) from the left hepatic artery. (C) Post-embolization celiac arteriography showed no more tumor staining and occlusion 
of the tumor supplying artery.
(CT) and magnetic resonance imaging (MRI) (Fig. 1A-B and 
1C-D, respectively). There was no vascular invasion and no 
intraabdominal lymphadenopathy. On positron emission tomo-
graphy-CT, maximum standardized uptake value for the mass 
was 6.3 without evidence of distant metastasis. Overall, early 
stage of HCC was assigned according to the Barcelona- 
Clinic-Liver-Cancer (BCLC) HCC staging system.
1
Surgical resection was recommended for the treatment of the 
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Figure 3. Complete necrosis of a previously noted lesion without remnant or new enhancement was observed (A: arterial phase, B: 
portal phase).
Figure 4. Regression in the size of the necrotic lesion (3 cm diameter) without definite evidence of recurrence was noted on six-month 
post-embolization MRI (A: arterial phase, B: delayed phase). 
HCC, however, he refused the surgical treatment. TACE using 
DEB was performed after obtaining written informed consent for 
the procedure. During the first TACE session, hepatic angiogram 
revealed a definite hypervascular mass supplied by a small 
branch of the left hepatic artery without apparent arteriovenous 
shunt (Fig. 2A-B). After positioning the microcatheter tip at the 
left hepatic artery close to the tumor-feeding branch, a mixture of 
DEB (DC Bead
®, 1 vial of 300~500 μm diameter, Biocompatibles, 
UK) loaded with doxorubicin (50 mg) and contrast agent was 
infused until the flow through the tumor-feeding artery was 
slowed down. After the infusion, angiogram showed occluded 
tumor-feeding branch and no tumor staining (Fig. 2C).
He had no serious adverse event after embolization except 
mild abdominal pain that was controlled with oral analgesic 
(tramadol 50 mg per os tid). One-month post-embolization CT 
(Fig. 3A-B) and six-month post-embolization MRI (Fig. 4A-B) 
showed complete necrosis without viable portions. Follow-up 
α-fetoprotein level was 3.89 ng/mL, and PIVKA-II level was 21 
mAU/mL. This patient remains in good health without cancer 
recurrence 6 months after the procedure.
DISCUSSION
Although HCC arising in the caudate lobe is no common in 
clinical setting, it is problematic due to its deep anatomical 
location and close relationship with major vasculatures. Caudate 
lobe occupies the space below the hepatic hilum in close proximity 
to ductal and portal confluences and the proximal hepatic 
arteries, above the inferior vena cava.
4 Frequent invasion of 
the vessels and frequent formation of tumor thrombi in portal 
vein and inferior vena cava might contribute to intra- and 
extrahepatic metastases.
5 The limitations in proper therapeutic 
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approach to the lesion is clinically challenging. For these reasons, 
prognosis of caudate HCC is relatively poor.
5
Surgical resection has been generally regarded as curative 
method for HCC. Although HCC in caudate lobe is rare, 
resection would be the most effective treatment and provide 
long-term survival.
6 Recently, improvement in surgical technique 
enables successful resection of caudate HCC, however, several 
operative risks and HCC recurrence are still remained problems.
7-10 
As an alternative treatment modality, radiofrequency ablation 
was conducted to treat caudate HCC by several methods, i.e. 
conventional percutaneous, laparoscopy-assisted, or intra-operative 
approaches.
11-13 But the proximity to major vessels contains 
potential risk of complication and incomplete ablation related 
with heat sink effect.
In this case, patient’s stage according to BCLC criteria was 
early, proposed to be treated effectively by resection, liver 
transplantation or ablation.
1 Although TACE was not suitable as 
first-line therapy for such an early-staged patient, TACE can be 
performed in patients at the early stage in whom ablation cannot 
be performed because of tumor location or medical comorbidities.
1 
By reason of aforementioned treatment limitations and patient’s 
refusal of surgery TACE using DEB was performed, and as a 
result, therapeutic response was satisfying without any serious 
complications.
DEB are a new soft deformable device of spherical shape 
composed by a polyvinyl alcohol and a hydrophilic monomer 
that can be loaded with anthracycline derivatives such as 
doxorubicin.
14 So, drug-loaded beads can be delivered intra- 
arterially into the tumor and elute the chemotherapeutic effect.
3 
Previous studies have shown that TACE with DEB results in 
promising efficacy and low toxicity.
15-17 Post-embolization 
syndrome, cholecystitis, liver abscess, and skin rash were 
reported as procedure-related complications.
17 In recent European 
multicenter comparative study, 212 patients with Child-Pugh 
A/B cirrhosis and large and/or multinodular, unresectable HCC 
(BCLC classification A or B) were randomized to receive either 
conventional TACE or DEB-TACE. According to the per- 
protocol analysis, objective response rate in the DEB-TACE 
group was 52%. In subgroup analysis, patients with more 
advanced disease-defined as Child-Pugh stage B, Eastern 
Cooperative Oncology Group performance status 1, bilobular or 
recurrent disease-had a significantly greater objective response 
rate (53%) in the DEB-TACE group.
18
We cannot assert the efficacy if the patient underwent 
conventional TACE instead of DEB-TACE. Terayama et al 
reported that cumulative local recurrence rate after subsegmental 
TACE for caudate HCC was very high compared with recurrence 
rate after subsegmental TACE for HCC in the other segments, 
and technical success rate of the procedure was relatively low 
(around 70%).
19 In previous study that analyzed explants after 
pre-transplant conventional TACE, a total or at least subtotal 
necrosis (≥ 80%) was noted in 30% on the liver explants, and half 
of the explants showed tumor necrosis less than 50%.
20 However, 
experimental study has shown that complete tumor destruction 
was observed in the DEB-treated animals sacrificed 7 days after 
treatment.
3 It means that DEB could be a potential curative 
therapeutic modality for HCC if there is no problem regarding 
embolization procedures. 
We report a case of caudate HCC successfully treated with 
DEB-TACE. TACE using this new agent could be an alternative 
therapy or downstaging method for the caudate HCC patients 
who are not eligible to conventional treatment including surgical 
resection.
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